Navigation Links
Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
Date:4/22/2010

GREENWOOD VILLAGE, Colo., April 22 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced that it has entered into a letter of intent (LOI) to acquire DMI Biosciences, Inc.

This acquisition will give AMPIO access to all rights, royalties and patents associated with a drug that treats premature ejaculation (P.E.) recently licensed to a specialty pharmaceutical company after demonstrating safety and efficacy in a Phase II clinical trial. This P.E. drug is protected by multiple U.S. and International patents, and is currently undergoing Phase III clinical trials in Europe.  

"Premature ejaculation is an under-reported condition that we believe affects substantially more men than erectile dysfunction (E.D.)", noted Chief Scientific Officer Dr. David Bar-Or, who developed the drug during his tenure at DMI Biosciences, Inc. "Consequently we know there is a serious need for a product that can treat this sexual dysfunction. " said Dr. Bar-Or.

"Among the assets being acquired in this stock purchase are a number of patent applications on combination drugs that would treat P.E. and E.D. in a single tablet," said Don Wingerter, Ampio's chief executive officer.  "Dr. Bar-Or is confident we can continue to develop safe and effective solutions for these types of medical conditions."

"The structure of this transaction will include a tax free exchange to the shareholders and we anticipate working diligently to complete the transition from the L.O.I. to a final agreement," Mr. Wingerter continued. "This agreement has the potential to provide AMPIO with a royalty stream that could begin as early as 2011.  Because of a confidentiality agreement, AMPIO cannot at this time disclose the licensee for the drug that is executing the Phase III trial.  The acquisition of the P.E. drug by AMPIO enhances our portfolio of drugs that currently focus on alleviating diabetic and inflammatory conditions."

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. develops drugs to treat metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The company's product pipeline includes certain FDA approved drugs, now targeted at new clinical indications protected by Ampio intellectual property, and new molecular entities ("NMEs"). The company's development of new uses for previously approved drugs is expected to result in reduced approval timelines, lower costs and decreased risks of clinical failure. The company is actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's near term and long term product development programs.

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks and uncertainties, such as statements of Ampio's plans, objectives, expectations and intentions. Forward-looking statements are generally identified by words, such as "projects," "believes," "anticipates," "plans," "expects," "will," and "would," and similar expressions that are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of Ampio to be materially different from those expressed or implied by forward-looking statements. Actual events may differ materially from those mentioned in these forward-looking statements because of a number of risks and uncertainties. A discussion of factors affecting Ampio's business and prospects is contained in Ampio's periodic filings with the Securities and Exchange Commission, including Ampio's Report on Form 8-K filed on March 8, 2010 with the Securities and Exchange Commission. Ampio undertakes no obligation to publicly update or revise any forward looking statements or to make any other forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by the securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and that undue reliance should not be placed on such statements.

Investor contact: Redwood Consultants, LLC,  Tel: +1 415-884-0348

(www.ampiopharma.com)


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
2. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
3. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
6. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
10. Biostar Pharmaceuticals Approved for Listing on NASDAQ Global Market
11. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017   ... will migrate its Amadeus precision medicine platform ... Health,s software currently manages over 110 million patient records ... approach to developing cloud-based, big data solutions built on ... Director of Healthcare and Life Sciences. "The AWS Cloud ...
(Date:2/20/2017)... Research and Markets has announced the addition of the ... report to their offering. ... An increasing number of patients suffering ... tension free repair procedures and increasing demand for minimally invasive ... market. However, Inconsistent reimbursement and the high cost of hernia ...
(Date:2/20/2017)... 20, 2017 According to a new market research ... powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End ... The market is projected to reach USD 52.37 Billion by 2021 from ... forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of touch ... 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... Tampa, FL (PRWEB) , ... February 20, 2017 ... ... $20,000 gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a ... ultrasonic waves. The gift was facilitated by the Pepin Family Foundation. , “We ...
(Date:2/19/2017)... ... 2017 , ... Orbita, Inc., a leading provider ... Healthwise ® at HIMSS 2017 to showcase a breakthrough in remote ... technology and services, will demonstrate a voice-powered knowedge assistant based on Orbita ...
(Date:2/18/2017)... ... , ... Park Cities Pet Sitter President, Joette White, has been featured on ... The episode, which was posted this week, features a 30-minute interview of White ... Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business ...
Breaking Medicine News(10 mins):